Federal contract award
75N95024C00020
MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE. PERIOD OF PERFORMANCE: 7/10/2024-7/9/2025. N01DA-24-8949
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIDA |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST NO FEE |
| Obligations | $3.0M |
| Current contract value | $3.0M |
| Potential contract value / ceiling | $7.8M |
| Start date | Jul 10, 2024 |
| Current end date | Jul 9, 2027 |
| Potential end date | Jul 9, 2029 |
| Latest award activity | Aug 10, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 10, 2026 | P00005 | $0 | EO14398. MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE. PERIOD OF PERFORMANCE: 7/10/2024-7/09/2027. N01DA-24-8949 |
| Jun 17, 2026 | P00004 | $894.2K | MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE. PERIOD OF PERFORMANCE: 7/10/2024-7/09/2027. N01DA-24-8949 |
| May 8, 2026 | P00003 | $46.6K | MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE. PERIOD OF PERFORMANCE: 7/10/2024-7/09/2026. N01DA-24-8949 |
| Jul 9, 2025 | P00002 | $866.8K | EOI::IMPLEMENTING THE PRESIDENT'S DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE (MARCH 19, 2025)::EOI MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE. PERIOD OF PERFORMANCE: 7/10/2024-7/09/2026. N01DA-24-8949 |
| Mar 6, 2025 | P00001 | $0 | MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE. PERIOD OF PERFORMANCE: 7/10/2024-7/9/2025. N01DA-24-8949 |
| Jul 9, 2024 | 0 | $1.2M | MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE. PERIOD OF PERFORMANCE: 7/10/2024-7/9/2025. N01DA-24-8949 |
Estimated positioning window
Jul 9, 2028 – Jan 9, 2029
50/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 50/100. Available recorded signals: 45 points.
- Contract end 2029-07-09 (981 days from calculation)
- +15 points
- 173 historical awards in this buyer and category group
- +15 points
- 6 recorded award transactions
- +10 points
- Latest award action: 2026-08-10
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.